COMPANY

Sirius Therapeutics

FDA-cleared device company Clinical Phase 2

Keywords: RNA therapeutics siRNA metabolic Thrombus Coronary Artery Disease Peripheral Arterial Disease Venous Thromboembolism Hyperlipoproteinemia (a) Thrombosis SRSD107 SRSD384 SRSD216

Profile checked Oct 10, 2026

6Trials (company is sponsor)

Timeline

2026-06 Trial start Phase 1/Phase 2: A Study of SRSD384 in Overweight or Obese Participants source ↗
Sep 16, 2025 Trial start Phase 2: A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA source ↗
Apr 7, 2025 Trial start Phase 1/Phase 2: A Study of SRSD216 in Patients With Elevated Lipoprotein (a) source ↗
Mar 11, 2025 Trial start Phase 2: A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease source ↗
Mar 29, 2024 Trial start 1: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRSD107 in Healthy Chinese Subjects source ↗
Jan 23, 2024 Trial start 1: A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants source ↗

Upcoming milestones

2027-10 (ESTIMATED) · Phase 1/Phase 2 · A Study of SRSD384 in Overweight or Obese Participants · NCT07557355
2027-12 (ESTIMATED) · Phase 2 · A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease · NCT07318155

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT07655427	A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRSD107 in Healthy Chinese Subjects	1	Completed	Mar 29, 2024	Mar 2, 2025 (actual)
NCT07557355	A Study of SRSD384 in Overweight or Obese Participants	Phase 1/Phase 2	Not yet recruiting	2026-06	2027-10 (estimated)
NCT07318155	A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease	Phase 2	Recruiting	Mar 11, 2025	2027-12 (estimated)
NCT07140523	A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA	Phase 2	Recruiting	Sep 16, 2025	Jun 30, 2026 (estimated)
NCT07172646	A Study of SRSD216 in Patients With Elevated Lipoprotein (a)	Phase 1/Phase 2	Recruiting	Apr 7, 2025	2026-05 (estimated)
NCT06116617	A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants	1	Completed	Jan 23, 2024	Dec 9, 2024 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗